Insmed (INSM) Stock Forecast & Price Target
Score
Insmed Incorporated price target
| INSM | |
|---|---|
| Low | $154.00 |
| Average | $191.06 |
| High | $235.00 |
| Upside vs current price | +57.5% |
The average target of $191.06 is +57.5% versus the current INSM price of $121.33.
Insmed Incorporated analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 5 |
| Buy | 18 |
| Hold | 1 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
24 analysts cover INSM.
Insmed Incorporated EPS and revenue estimates
Published annual figures for INSM on this page are 2026 EPS $-1.62, 2027 EPS $0.72. Coverage under three analysts is omitted.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $-1.62 | $1.86B |
| 2027 | $0.72 | $3.00B |
Is Insmed Incorporated a buy or sell?
Of the 24 analysts covering Insmed Incorporated, 23 rate it a buy (5 strong buy and 18 buy), 1 rates it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The INSM consensus label is Buy, beside 23 buy-side ratings and 0 sell-side ratings.
The average target of $191.06 implies +57.5% versus the current price of $121.33.
The INSM rating block is 24 published views with a Buy label. It does not tell you whether to buy or sell.
Reading the Insmed Incorporated forecast
A wide spread is the story on INSM. Targets run from $154.00 to $235.00, with $191.06 as the average.
The gap from the $121.33 price to the INSM average is +57.5%.
The INSM rating mix is lopsided rather than split: 23 of 24 analysts are on the buy side, 1 is at hold, and 0 are on the sell side, and the published consensus is Buy.
The latest INSM actions do not point one way: 0 up and 1 down.
INSM targets have not moved much: $190.50 recently, $190.00 across the quarter.
the Insmed Incorporated is followed by 24 analysts, so the range matters more than any one target.
Insmed Incorporated forecast questions
What is the INSM price target?
The published range for INSM is $154.00 to $235.00, with an average of $191.06. That average is +57.5% versus the current price of $121.33.
Is Insmed Incorporated a buy or sell?
Of the 24 analysts covering Insmed Incorporated, 23 rate it a buy, 1 rates it a hold, and 0 rate it a sell. The consensus is Buy, leaving INSM at 23 buy ratings, 1 holds, and 0 sells.
What is the EPS estimate for Insmed Incorporated?
Analyst EPS estimates for Insmed Incorporated: 2026 $-1.62, 2027 $0.72.
What is the revenue estimate for Insmed Incorporated?
Analyst revenue estimates for Insmed Incorporated: 2026 $1.86B, 2027 $3.00B.
How many analysts cover INSM?
24 analysts cover INSM. Their consensus on INSM is Buy, across those 24.